1. Home
  2. INSM vs ESLT Comparison

INSM vs ESLT Comparison

Compare INSM & ESLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • ESLT
  • Stock Information
  • Founded
  • INSM 1988
  • ESLT 1966
  • Country
  • INSM United States
  • ESLT Israel
  • Employees
  • INSM N/A
  • ESLT N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • ESLT Military/Government/Technical
  • Sector
  • INSM Health Care
  • ESLT Industrials
  • Exchange
  • INSM Nasdaq
  • ESLT Nasdaq
  • Market Cap
  • INSM 17.3B
  • ESLT 18.3B
  • IPO Year
  • INSM 2000
  • ESLT 1996
  • Fundamental
  • Price
  • INSM $102.68
  • ESLT $438.47
  • Analyst Decision
  • INSM Strong Buy
  • ESLT
  • Analyst Count
  • INSM 17
  • ESLT 0
  • Target Price
  • INSM $106.80
  • ESLT N/A
  • AVG Volume (30 Days)
  • INSM 4.1M
  • ESLT 200.0K
  • Earning Date
  • INSM 08-07-2025
  • ESLT 08-13-2025
  • Dividend Yield
  • INSM N/A
  • ESLT 0.50%
  • EPS Growth
  • INSM N/A
  • ESLT 55.53
  • EPS
  • INSM N/A
  • ESLT 7.89
  • Revenue
  • INSM $381,030,000.00
  • ESLT $7,169,721,000.00
  • Revenue This Year
  • INSM $28.03
  • ESLT $14.18
  • Revenue Next Year
  • INSM $120.54
  • ESLT $10.31
  • P/E Ratio
  • INSM N/A
  • ESLT $55.12
  • Revenue Growth
  • INSM 20.77
  • ESLT 16.86
  • 52 Week Low
  • INSM $60.40
  • ESLT $175.30
  • 52 Week High
  • INSM $102.70
  • ESLT $476.04
  • Technical
  • Relative Strength Index (RSI)
  • INSM 78.76
  • ESLT 59.31
  • Support Level
  • INSM $98.46
  • ESLT $407.76
  • Resistance Level
  • INSM $102.00
  • ESLT $456.50
  • Average True Range (ATR)
  • INSM 3.50
  • ESLT 14.14
  • MACD
  • INSM 2.61
  • ESLT 1.92
  • Stochastic Oscillator
  • INSM 99.61
  • ESLT 44.98

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About ESLT Elbit Systems Ltd.

Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security, and commercial flight capabilities. Its systems and solutions may be installed on new platforms, or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company markets its systems and products as a prime contractor or as a subcontractor to government, defense, and homeland security contractors world wide.

Share on Social Networks: